Impact of FIGO type 3 uterine fibroids on in vitro fertilization outcomes: A systematic review and meta‐analysis
International Journal of Gynecology & Obstetrics · 2023-11 · 163 (2) · 528-539
DOI: 10.1002/ijgo.14838 ↗Kurz gefasst
Metaanalyse in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 15.05.2023. Verfasst von Alessandro Favilli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Obstetrics and Gynecology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Infertility, Female, Leiomyoma, Myoma. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Background
The effect of FIGO (the International Federation of Gynecology & Obstetrics) type 3 myomas on in vitro fertilization (IVF) is uncertain.
Objectives
To evaluate whether FIGO type 3 myomas affect IVF outcomes, through a systematic review and meta‐analysis (CRD42022379700). Search strategy Electronic databases were searched until November 15, 2022. Selection criteria Studies evaluating the effects of FIGO type 3 myomas on IVF outcome. Data collection and analysis Pooled results were expressed as odds ratios (OR) with 95% confidence intervals (CI). Heterogeneity was assessed using Higgins I 2 . Sources of heterogeneity were explored with sensitivity and subgroup analyses. Main results In total, 1020 patients were included: 324 with FIGO type 3 myomas and 696 controls (without myomas). A pooled data analysis showed a significantly lower live birth rate (OR 2.16, 95% CI 1.55–3.01, I 2 = 0%, P < 0.00001), clinical pregnancy rate (OR 2.06, 95% CI 1.52–2.81, I 2 = 0%, P < 0.00001), and implantation rate (OR 1.77, 95% CI 1.35–2.32, I 2 = 0%, P < 0.00001) in women with untreated myomas compared with controls. The number and size of fibroids correlated with a worsening of IVF outcomes.
Conclusions
FIGO type 3 myomas are significantly associated with a lower implantation rate, cumulative pregnancy rate, and live birth rate. Furthermore, their deleterious effect on the outcome of IVF increases further with increasing size and number. Nevertheless, no firm conclusions could be drawn about the potential benefits of surgery for FIGO type 3 uterine fibroids on IVF outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Obstetrics and Gynecology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
- Unit of Gynecologic Oncology, ARNAS "Civico - Di Cristina - Benfratelli", Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy.
- Department of Biomedical and Human Oncological Science (DIMO), 1st Unit of Obstetrics and Gynecology, University of Bari, Policlinico, Bari, Italy.
ORCID-Profile: Alessandro Favilli, Andrea Etrusco, Vito Chiantera, Antonio Simone Laganà, Ettore Cicinelli, Sandro Gerli, Amerigo Vitagliano
Zitieren
APA
Favilli, A., Etrusco, A., Chiantera, V., Laganà, A. S., Cicinelli, E., Gerli, S., & Vitagliano, A. (2023). Impact of FIGO type 3 uterine fibroids on in vitro fertilization outcomes: A systematic review and meta‐analysis. International Journal of Gynecology & Obstetrics, 163(2), 528-539. https://doi.org/10.1002/ijgo.14838
Vancouver
Favilli A, Etrusco A, Chiantera V, Laganà AS, Cicinelli E, Gerli S, et al. Impact of FIGO type 3 uterine fibroids on in vitro fertilization outcomes: A systematic review and meta‐analysis. International Journal of Gynecology & Obstetrics. 2023;163(2):528-539. doi:10.1002/ijgo.14838
BibTeX
@article{Favilli2023,
author = {Favilli, Alessandro and Etrusco, Andrea and Chiantera, Vito and Laganà, Antonio Simone and Cicinelli, Ettore and Gerli, Sandro and Vitagliano, Amerigo},
title = {Impact of FIGO type 3 uterine fibroids on in vitro fertilization outcomes: A systematic review and meta‐analysis},
journal = {International Journal of Gynecology & Obstetrics},
year = {2023},
volume = {163},
number = {2},
pages = {528--539},
doi = {10.1002/ijgo.14838}
}
EUVIMED